Effects of scopolamine on visual evoked potentials in aging and dementia

Electroencephalogr Clin Neurophysiol. 1991 Sep-Oct;80(5):347-51. doi: 10.1016/0168-5597(91)90081-8.

Abstract

The unusual combination of a normal pattern reversal VEP and a delayed flash VEP has been reported in patients with dementia of Alzheimer's type (DAT). Hyoscine hydrobromide has been reported to produce a similar VEP abnormality in young, healthy subjects. In the present study, we assessed the relative sensitivity of DAT patients and healthy young, middle-aged and elderly subjects to temporary cholinergic blockade. We report VEP latency values following 3 doses of scopolamine and after a peripheral anticholinergic agent. Flash P2 latency was not significantly slower in DAT patients than in the healthy elderly. Scopolamine increased P2 latency in the young controls but did not affect any other group. The pattern reversal P100 was normal in DAT, and a significant increase in latency occurred following scopolamine administration in both the control and patient groups.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aging / physiology*
  • Alzheimer Disease / physiopathology*
  • Electroencephalography
  • Evoked Potentials, Visual / drug effects*
  • Humans
  • Middle Aged
  • Parasympatholytics / metabolism
  • Parasympatholytics / pharmacology
  • Pattern Recognition, Visual / drug effects
  • Reaction Time / drug effects
  • Scopolamine / pharmacology*

Substances

  • Parasympatholytics
  • Scopolamine